431
Views
53
CrossRef citations to date
0
Altmetric
Review

Walking impairment in patients with multiple sclerosis: exercise training as a treatment option

, &
Pages 767-774 | Published online: 16 Nov 2010

References

  • MayrWTPittockSJMcClellandRLJorgernsenNWNoseworthyJHRodriquezMIncidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000Neurology2003611373137714638958
  • National Multiple Sclerosis SocietyMultiple Sclerosis Information SourcebookNew York, NYInformation Resource Center and Library of the National Multiple Sclerosis Society2005
  • HemmerBNesslerSZhouDKieseierBHartungHPImmunopathogenesis and immunotherapy of multiple sclerosisNat Clin Pract Neurol2006220121116932551
  • TrappBDNaveKAMultiple sclerosis: an immune or neurodegenerative disorderAnn Rev Neurosci20083124726918558855
  • BjartmarCTrappBDAxonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequencesCurr Opin Neurol20011427127811371748
  • MartinCLPhillipsBAKilpatrickTJGait and balance impairment in early multiple sclerosis in the absence of clinical disabilityMult Scler20061262062817086909
  • KurtzkeJFHistorical and clinical perspectives of the Expanded Disability Status ScaleNeuroepidemiology2008311918535394
  • GoldmanMDMotlRWRudickRAPossible clinical outcome measures for clinical trials in patients with multiple sclerosisTher Adv Neurol Disord20103229239
  • ConfavreuxCVukusicSAdelinePEarly clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic processBrain200312677078212615637
  • ConfavreuxCVukusicSMoreauTAdeleinePRelapses and progression of disability in multiple sclerosisN Eng J Med200034314301438
  • SchwidSRGoodmanADMattsonDHThe measurement of ambulatory impairment in multiple sclerosisNeurology1997495141914249371932
  • GoldmanMDMarrieRACohenJAEvaluation of the six-minute walk in multiple sclerosis subjects and healthy controlsMult Scler200814338339017942508
  • OlgiatiRJacquetJdi PramperoPEEnergy cost of walking and exertional dypsnea in multiple sclerosisAm Rev Respir Dis1986134100510103777662
  • MotlRWSuhYDlugonskiDOxygen cost of treadmill and over-ground walking in mildly disabled persons with multiple sclerosisNeurol Sci. Epub 2010 Aug 27
  • MotlRWDlugonskiDSuhYMultiple Sclerosis Walking Scale-12 and oxygen cost of walkingGait Posture20103150651020226676
  • ThoumiePLamotteDCantalloubeSFaucherMAmarencoGMotor determinants of gait in 100 ambulatory patients with multiple sclerosisMult Scler20051148549116042234
  • DurstineJLPainterPFranklinBAMorganDPitettiKHRobertsSOPhysical activity for the chronically ill and disabledSports Med20003020721910999424
  • WhiteLJCastellanoVExercise and brain health – Implications for multiple sclerosis. Part I – Neuronal growth factorsSports Med2008389110018201113
  • MotlRWMcAuleyESnookEMPhysical activity and multiple sclerosis: a meta analysisMult Scler20051145946316042230
  • GarrettMCooteSMultiple sclerosis and exercise in people with minimal gait impairment – a reviewPhys Ther Rev200914169180
  • MotlRWGoldmanMDPhysical inactivity, neurological disability, and cardiorespiratory fitness in multiple sclerosisActa Neurol Scand2010
  • Kent-BraunJANgAVCastroMStrength, skeletal muscle composition, and enzyme activity in multiple sclerosisJ Appl Physiol199783199820049390973
  • de HaanAde RuiterCJvan der WoudeLHVJongenPJHContractile properties and fatigue of quadriceps muscles in multiple sclerosisMuscle Nerve2000231534154111003788
  • HeckmanGAMcKelvieRSCardiovascular aging and exercise in healthy adultsClin J Sports Med200818479485
  • Ploutz-SnyderLLManiniTPloutz-SnyderRJWolfDAFunctionally relevant thresholds of quadriceps femoris strengthJ Gerontol A Biol Sci Med Sci200257B144B15211909879
  • WatersSMulroySThe energy expenditure of normal and pathological gaitGait Posture1999920723110575082
  • RossiSFurlanRde ChiaraVExercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitisNeurobiol Dis200836515919591937
  • BouchardCShephardRJPhysical activity, fitness, and health: the model and key conceptsBouchardCShephardRJStephensTPhysical Activity, Fitness, and Health: International Proceedings and Consensus StatementChampaign, ILHuman Kinetics19947788
  • WhiteLJDressendorferRHExercise and multiple sclerosisSports Med2004341077110015575796
  • RietbergMBBrooksDUitdehaagBMJKwakkelGExercise therapy for multiple sclerosisCochrane Database System Review2004
  • MotlRWGosneyJLEffect of exercise training on quality of life in multiple sclerosis: a meta-analysisMult Scler20081412913517881388
  • MotlRWMcAuleyESnookEMScottJAValidity of physical activity measures in ambulatory individuals with multiple sclerosisDisabil Rehabil2006281151115616966236
  • MotlRWSnookEMConfirmation and extension of the validity of the Multiple Sclerosis Walking Scale-12 (MSWS-12)J Neurol Sci2008268697318061618
  • WeikertMMotlRWSuhYMcAuleyEWynnDAccelerometry in persons with multiple sclerosis: Measurement of physical activity or walking mobilityJ Neurol Sci201029061120060544
  • MotlRWMcAuleyEWynnDSuhYWeikertMDlugonskiDSymptoms and physical activity among adults with relapsing-remitting multiple sclerosisJ Nerv Ment Dis201019821321920215999
  • MotlRWMcAuleyEWynnDVollmerTLifestyle physical activity and walking impairment over time in relapsing-remitting multiple sclerosis: results from a panel studyAm J Phys Med Rehabil2010
  • SnookEMMotlRWEffect of exercise training on walking mobility in multiple sclerosis: a meta-analysisNeurorehabil Neural Repair20092310811618948413
  • FilippiniGMunariLIncorvaiaBInterferons in relapsing remitting multiple sclerosis: a systematic reviewLancet200336154555212598138
  • van DiemenHAPolmanCHvan DongenTMThe effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over studyAnn Neurol1992321231301510353
  • BeverCTJrYoungDAndersonPAThe effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trialNeurology199444105410598208399
  • SchwidSRPetrieMDMcDermottMPTierneyDSMasonDHGoodmanADQuantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosisNeurology1997488178219109861
  • StefoskiDDavisFAFitzsimmonsWELuskinSSRushJParkhurstGW4-Aminopyridine in multiple sclerosis: prolonged administrationNeurology199141134413481891078
  • GoodmanADBrownTRKruppLBSustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialLancet2009373966573273819249634
  • KatrychOSimoneTMAzadSMousaSADisease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomesCNS Neurol Disord Drug Targets2009851251919811446
  • KhanOLeistTPVollmerTLZamvilSSInvestigating multiple sclerosis: targeting therapeutic optionsInt J MS Care.200810Suppl520
  • KraftGHRehabilitation still the only way to improve function in multiple sclerosisLancet19993542016201710636362